Imuldosa

Ustekinumab, the active ingredient in Imuldosa, is an interleukin‑12/23 inhibitor presented as a subcutaneous formulation for injection use. It is indicated for the treatment of plaque psoriasis, psoriatic arthritis, and moderately to severely active Crohn’s disease in appropriate adult patients.

GNH USA supplies Imuldosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Imuldosa (ustekinumab) targets the interleukin‑12/23 pathway and is used in several immune‑mediated inflammatory conditions.

Plaque psoriasis: reduces skin lesions and improves quality of life in adult patients. Psoriatic arthritis: alleviates joint inflammation and pain, improving functional ability. Moderately to severely active Crohn’s disease: induces and maintains remission of intestinal inflammation in adults.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Upper respiratory tract infections: mild cold‑like symptoms. - Headache: transient and usually mild. - Fatigue: general feeling of tiredness. - Nausea: occasional upset stomach. - Diarrhea: loose stools that may be self‑limiting.

Serious or Rare Side Effects: - Serious infections: including tuberculosis, bacterial, fungal, or viral infections. - Malignancies: rare reports of lymphoma or skin cancers. - Severe hypersensitivity: anaphylaxis or angioedema. - Inflammatory bowel disease exacerbation: worsening of Crohn’s disease symptoms. - Demyelinating disorders: new or worsening neurologic conditions. - Cardiovascular events: rare cases of myocardial infarction or stroke.

Before initiating therapy, patients should be evaluated for infection risk and immunization status.

Screen for active infections: assess and treat any current infection before starting. Monitor for signs of infection: advise patients to report fever, cough, or unusual symptoms promptly. Assess tuberculosis risk: perform TB screening (e.g., interferon‑gamma release assay) prior to treatment. Vaccination considerations: avoid live vaccines during therapy and schedule inactivated vaccines appropriately. Pregnancy and lactation: discuss potential risks with a healthcare professional; data are limited. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ustekinumab may interact with other agents that affect immune function.

Major Interactions (Avoid): - Live vaccines: may cause severe infection when administered concurrently. - Concurrent biologic immunosuppressants: increased risk of serious infections. - High‑dose systemic immunosuppressants (e.g., methotrexate): heightened immunosuppression.

Moderate Interactions (Monitor Closely): - Corticosteroids: may augment infection risk; monitor patient closely. - Antifungal agents (e.g., azoles): additive immunosuppressive effect; observe for infections. - Inactivated vaccines: possible reduced efficacy; assess immune response when needed.